When Does Vertex Report Earnings? August 3, and Options Are Pricing 6% for a Stock That Fell 20% on This Print Last Year

TL;DR

• Vertex reports Q2 2026 after the close on Monday, August 3, with the call at 4:30pm ET.
• Consensus: adjusted EPS of about $4.85 on revenue of about $3.23 billion, up roughly 8.8%.
• Options are pricing a move of about 6.2%. The same quarter last year produced a 20.6% drop, and the quarter after that produced a 10% drop. Neither was caused by the revenue line.
• Both of those falls came from pipeline news attached to the release, not the P&L. In August 2025 it was VX-993 missing its primary endpoint in acute pain.
• The stock closed $477.10 on July 31, up about 17% year to date. The number that matters most on Monday is the zimislecel filing timeline, which management said it would update "in coming months".

When Does Vertex Report Earnings?

The short answer: after the close on Monday, August 3, 2026, with the conference call at 4:30pm ET.

That is 9:30pm BST in the UK. Vertex shares the evening with Palantir, which reports the same day at 5:00pm ET, and opens a week that runs through AMD on Tuesday and the July jobs report on Friday.

What the Street Expects

Line	Q2 2026 consensus	Comparison
Adjusted EPS	~$4.85	up about 7% year over year
Revenue	~$3.23B	up about 8.8%
Trikafta / Kaftrio	~$2.45B	still the majority of the company
Full-year revenue guide	$12.95B to $13.1B	reaffirmed at Q1
Options implied move	~6.0% to 6.2%	median move over the past 8 quarters: 3.0%

Estimates are unusually tight. The Zacks consensus sits at $4.85, the most accurate contributing estimate at $4.80, and some data providers carry numbers as low as $4.74. A spread of eleven cents on a five dollar quarter tells you the analyst community thinks the arithmetic is settled.

It probably is. That is exactly the problem with treating this as an earnings print.

The Board

Six percent implied, against a name that has moved double digits on two of its last four prints.

The Reaction Has Not Come From the Numbers in Two Years

This is the part of the setup that is genuinely mispriced, and it is worth laying out as a list.

Report	Reaction
Nov 4, 2024	+5.73%
Feb 10, 2025	−3.14%
May 5, 2025	−10.03%
Aug 4, 2025	−20.60%

Look at last August specifically. Vertex reported EPS of $4.52 against $4.24 expected and revenue up double digits, then fell more than 20%. The quarter was a beat. What killed it was the accompanying pipeline update: the phase II study of VX-993, the next-generation oral Nav1.8 inhibitor, failed to show a statistically significant improvement on its primary endpoint in post-bunionectomy acute pain, and Vertex said it would not advance the drug into pivotal development as a monotherapy. Guidance was left unchanged on top of it.

So the pattern is clear. Vertex's revenue is boring and its releases are not. A cystic fibrosis franchise with near-monopoly economics does not surprise anyone by 3%. The pipeline does, in both directions, and Vertex staples pipeline news to its quarterly releases.

That is why an implied move of 6.0% to 6.2% is the interesting number here. It is roughly the right price for a quarter and roughly half the right price for a pipeline event, and you do not get to know in advance which one Monday is.

Here is the fair counter-argument, stated properly. The median move over Vertex's past eight quarters is only 3.0%, so on a typical print, selling a 6% straddle wins. The distribution is not the median: it is four quiet quarters and then a 20% day when a trial reads out. Selling premium here is picking up nickels in front of a machine that has run readers over twice in two years, and pre-earnings put volume running roughly two to one over calls suggests the professionals are positioned for the tail rather than the median.

The Four Things That Actually Decide Monday

1. Zimislecel, and the filing timeline. The type 1 diabetes islet cell programme resumed dosing after an internal manufacturing review, and management said it would share updated pivotal completion and filing timelines "in coming months". Monday is a coming month. A firm filing date is the single most valuable sentence Vertex can say, and a second delay is the single most damaging.

2. Journavx, in its second launch year. The non-opioid acute pain drug did $29 million in Q1 2026 and has passed one million prescriptions. That is real adoption and small revenue, which is normal for a launch fighting formulary battles. Vertex has guided to $500 million or more of non-CF revenue for the full year, and Journavx has to carry a chunk of it.

3. Alyftrek cannibalisation. Alyftrek passed $1 billion cumulative since launch. Most of that is Trikafta patients switching, which is fine strategically (Alyftrek is once-daily and carries fresh patent life) and messy optically, because the headline CF line grows slowly while the mix shifts underneath it. Watch the combined CF number, not either drug alone.

4. Casgevy's slope. $43 million in Q1 and 500 patient initiations. Gene therapy revenue recognises in lumps as patients move through the treatment centre network. One slow quarter is noise, two is a pattern.

Why Anyone Owns This Into the Print

Vertex is the rare large-cap growth story with nothing whatsoever to do with AI capex, which is a real portfolio property in a month where the entire market has traded on data centre spending. It has a protected franchise, no meaningful patent cliff before the next decade, and it is finally converting a pipeline into products after years of being a one-disease company.

The bear case is equally plain. You are paying a growth multiple for 8% growth, and the growth that justifies the multiple is all in drugs that have not been approved yet. That is the definition of a stock that trades on pipeline headlines.

The Options Angle

• Do not sell premium here just because 6.2% looks rich. That reflex cost readers money repeatedly in July, and this is the exact name where it is most likely to fail again: two of the last four prints cleared 10%.
• If you want to own the event, a straddle at roughly 6% of spot needs a move bigger than about $29 on a $477 stock. Last August delivered nearly $100. The August before that delivered almost nothing.
• For holders who want to keep the shares, a covered call struck well outside the implied move is defensible, but understand what you are doing: you are selling the upside of a zimislecel filing date to collect a week of premium.
• Live option prices for individual strikes could not be sourced at the time of writing, so the plays below are quoted against the implied move and the July 31 close.

Trade log

#	Stance	Structure	Strikes and expiry	Cost or credit	Spot at writing	Implied move	Breakeven
1	Long volatility	Long straddle	At-the-money, weekly expiry after Aug 3	~6.2% of spot, price not sourced	$477.10 (Jul 31, 2026 close)	±6.2%	needs a move beyond ±6.2%, about $29
2	Pass	Short strangle / premium selling	Wings outside ±6.2%	credit not sourced	$477.10	±6.2%	loses beyond ±6.2%
3	Income, holders only	Covered call	Strike above the implied move, roughly $510	premium not sourced	$477.10	±6.2%	caps upside above ~+7%

Row 2 is a recommendation with a P&L consequence and is logged so it gets scored. We are telling readers not to sell volatility into this print. If Vertex moves less than 6.2%, that pass is a loss.

The One-Line Read

Vertex reports after the close on Monday August 3 against a consensus of about $4.85 on $3.23 billion that almost nobody disputes, which is precisely why the quarter will not set the reaction: the last two double-digit moves in this stock both came from pipeline news bolted onto the release rather than from the P&L, and with options pricing only 6.2% against a 20.6% drop on this same print a year ago, the zimislecel filing timeline is worth more than every line on the income statement combined.